AstraZeneca Receives First Supply Agreement for University of Oxford’s ChAdOx1 nCoV-19 Vaccine Against COVID-19

AstraZeneca Receives First Supply Agreement for Oxford University’s ChAdOx1 nCoV-19 Vaccine Against COVID-19


  • AstraZeneca is collaborating with multiple countries and multilateral organizations to make the University of Oxford’s vaccine widely accessible across the globe in an equitable manner. AstraZeneca has received its first agreement for ~400M doses with a manufacturing capacity of 1B doses and anticipated first delivery in Sept’2020
  • BARDA has granted ~$1B to support the development, production and delivery of the vaccines. The development program includes P-III clinical trial with ~30,000 participants and a pediatric study
  • Additionally, the company is collaborating with CEPI, Gavi the Vaccine Alliance and the WHO for the fair allocation and distribution of the vaccine around the globe while the company is in discussions with the Serum Institute of India and other partners to increase production and distribution. AstraZeneca has finalized its license agreement with Oxford University for the vaccine, the licensing follows the global development and distribution agreement with the University’s Jenner Institute and the Oxford Vaccine Group

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: AstraZeneca

Related News: AstraZeneca Signs a Worldwide Development and Distribution Agreement with Oxford University for Vaccine Against COVID-19